Abstract
Pituitary apoplexy (PA) is a clinical condition characterised by a sudden increase in pituitary gland volume secondary to ischaemia and/or necrosis. Most cases occur in non-functioning pituitary adenoma but can also occur in functioning adenoma. Certain predisposing factors can result in PA and the use of gonadotropin-releasing hormone (GnRH) agonists for prostate cancer (PCa) is one such condition. Once diagnosed, both surgical and conservative management has been used for the treatment of PA. We present a case of a man in his late 50s who developed PA following treatment of PCa with leuprolide. His symptoms developed insidiously and he presented 6 months after symptom onset. Anterior pituitary hormone workup along with pituitary MRI confirmed the diagnosis of PA and patient was subsequently treated with adequate replacement of pituitary hormone with significant improvement in his symptoms. It is very important to keep a high index of suspicion for PA, especially among elderly patients receiving GnRH agonist treatment for PCa.
| Original language | English (US) |
|---|---|
| Article number | e248523 |
| Journal | BMJ Case Reports |
| Volume | 15 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 7 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- endocrine system
- malignant disease and immunosuppression
- pituitary disorders
- prostate cancer
- unwanted effects / adverse reactions
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS